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OBJECTIVE—The adipokine hormone leptin triggers signals in
the brain that ultimately lead to decreased feeding and increased
energy expenditure. However, obesity is most often associated
with elevated plasma leptin levels and leptin resistance. Suppres-
sor of cytokine signaling (SOCS)-3 and protein-tyrosine phospha-
tase 1B (PTP-1B) are two endogenous inhibitors of tyrosine
kinase signaling pathways and suppress both insulin and leptin
signaling via different molecular mechanisms. Brain-speciﬁc in-
activation of these genes individually in the mouse partially
protects against diet-induced obesity (DIO) and insulin resis-
tance. The aim of this study was to investigate possible genetic
interactions between these two genes to determine whether
combined reduction in these inhibitory activities results in syn-
ergistic, epistatic, or additive effects on energy balance control.
RESEARCH DESIGN AND METHODS—We generated mice
with combined inactivation of the genes coding for SOCS-3 and
PTP-1B in brain cells, examined their sensitivity to hormone
action, and analyzed the contribution of each gene to the
resulting phenotype.
RESULTS—Surprisingly, the Nestin-Cre mice used to mediate
gene inactivation displayed a phenotype. Nonetheless, combined
inactivation of SOCS-3 and PTP-1B in brain revealed additive
effects on several parameters, including partial resistance to DIO
and associated glucose intolerance. In addition, synergistic ef-
fects were observed for body length and weight, suggesting
possible compensatory mechanisms for the absence of either
inhibitor. Moreover, a SOCS-3–speciﬁc lean phenotype was re-
vealed on the standard diet.
CONCLUSIONS—These results show that the biological roles
of SOCS-3 and PTP-1B do not fully overlap and that targeting
both factors might improve therapeutic effects of their inhibition
in obesity and type 2 diabetes. Diabetes 59:3074–3084, 2010
O
besity is a major risk factor for insulin resis-
tance and type 2 diabetes as well as for cardio-
vascular diseases. Although identiﬁcation of
the adipokine hormone leptin (1) accelerated
progress in understanding mechanisms leading to obesity
and associated pathologies, much remains to be discov-
ered. Leptin acts on various brain regions including the
hypothalamus, ventral tegmental area, and hindbrain
(2–10) and regulates energy homeostasis by triggering
decreased food consumption and increased energy expen-
diture. Unfortunately, circulating leptin levels are elevated
in most obese humans, and treatment of these patients
with leptin was unsuccessful (11,12). Most obesity is
associated with central leptin resistance (13) that may
result from defects in leptin transport across the blood-
brain barrier (14–17) or inﬂammatory responses in the
mediobasal hypothalamus secondary to overnutrition
(18,19). Resistance may also result from dysregulation of
the leptin receptor intracellular signaling pathway, which
prevents appropriate transduction of the leptin signal.
Suppressor of cytokine signaling (SOCS)-3 and protein-
tyrosine phosphatase 1B (PTP-1B) suppress cytokine sig-
naling pathways, including the leptin pathway (20–23).
Interestingly, the Socs-3 gene is a target for signal trans-
ducer and activator of transcription (STAT) 3, which is a
crucial mediator of leptin signaling (24). SOCS-3 levels are
increased after leptin injection and in mice with diet-
induced obesity (DIO) (16,25–28). Chronic activation of
the leptin pathway generates a negative-feedback regula-
tory loop that is believed to alter central leptin signaling in
DIO. Hypothalamic PTP-1B levels are also modulated by
chronic leptin administration, inﬂammation, and high-fat
diet (HFD) feeding (23,29–32).
Genetic inactivation of the Socs-3 or Ptpn1 (PTP-1B)
genes in mouse brain, like whole-body Socs-3 haploinsuf-
ﬁciency or Ptpn1 knockout, leads to enhanced leptin
sensitivity and resistance to DIO (33–37). However, possi-
ble interactions between the two genes have not been
explored. In a system where both genes are inactivated,
absence of genetic interaction is expected to be revealed
by the addition of the effects generated by the absence of
either gene. In contrast, evidence of genetic interaction
may be invoked if there is a deviation from such additive
effects: this includes synergistic and dominant epistatic
effects. In addition, combined inactivation of both genes
may reveal new pathways in which both SOCS-3 and
PTP-1B play a regulatory role. We therefore decided to
investigate possible interactions between Socs-3 and
Ptpn1 by generating mice with combined gene inactivation
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surprising metabolic phenotype displayed by the Nestin-
Cre mice, inactivation of both genes in brain revealed
additive effects on most parameters studied. Interestingly,
synergistic effects were observed for body length and
weight, and some factor-speciﬁc phenotypes were also
revealed.
RESEARCH DESIGN AND METHODS
Generation of Nestin-Cre;Ptpn1
lox/lox;Socs-3
lox/lox mice. Socs-3
lox mice
were obtained from Dr. Yoshimura and Ptpn1
lox mice from Drs. Bence, Kahn,
and Neel (35,38). Mice were backcrossed more than six times on a C57BL/6
(Jackson Laboratories) background. Nestin-Cre mice were from Jackson
Laboratory (strain no. 377). Details of the breeding strategy can be found in
the online appendix (available at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-1436/DC1). Animal protocols were approved by the institu-
tional animal care and use committee.
HFD studies. Nestin-Cre (n  7), ﬂoxed (n  15), Socs-3 (n  9), Ptpn1 (n 
10), and double-mutant (n  13) mice were fed a diet containing 45% kcal from
fat and 35% kcal from carbohydrates (Research Diets no. D12451) starting at
6 weeks of age. Body weight was measured weekly. Fat mass was measured
by EchoMRI (Echo Medical Systems) after 13 weeks on the diet. Oxygen
consumption, heat production, and locomotor activity were measured using a
Comprehensive Lab Animal–Monitoring System (CLAMS; Columbia Instru-
ments) over 48 h, following a 2-day acclimation period. Ambulatory activity
was determined by infrared beam breaks along the x- and y-axes. Food intake
was manually measured over 2 consecutive days from single-caged animals
after a period of habituation. Mice were killed after 21–30 weeks on the diet.
Hormonal assays. Blood was collected from tail nicks in the morning
between 0800 h and 1000 h for fed measurements. For studies on the HFD,
mice were food deprived for 6 h prior to bleeding in the afternoon. Total
plasma insulin-like growth factor (IGF)-1 (Diagnostics Systems Laboratories),
leptin, and insulin (CrystalChem) were assayed by enzyme-linked immunosor-
bent assays.
Glucose and insulin tolerance tests. For glucose tolerance tests, mice were
fasted overnight (15–16 h) and intraperitoneally injected with glucose (1 mg/g
body wt). For insulin tolerance tests, mice were fasted for 6 h prior to
intraperitoneal injections with insulin (0.5 mU/g body wt Humulin R; Eli Lilly).
Leptin sensitivity tests. Standard diet–fed mice were single housed and
habituated to handling for 5 days prior to injections. Mice and food were
weighed everyday at 0900 h. Measurements for the last 3 days before
injections were averaged and used as baseline values. Saline was intraperito-
neally administered for 3 days, followed by mouse recombinant leptin (A.F.
Parlow, National Hormone and Peptide Program) twice daily for 3 days (0900
h and 1800 h; dose, 0.75 g/g; total daily dose, 1.5 g/g).
Immunohistochemistry for phosphorylated STAT3 (pSTAT3) (Tyr 705; Cell
Signaling Technology) was performed on free-ﬂoating sections. Overnight-
fasted mice were intraperitoneally injected with leptin (3 g/g) or saline (PBS)
and transcardially perfused with 10% formalin under deep anesthesia 3 h after
injections. DAB (diaminobenzidine) was used for revelation and hematoxylin
for counterstaining. Imaging was carried out on an Axio Imager.A1 micro-
scope (Zeiss), processed with Adobe Photoshop software, and analyzed with
MacBiophotonics Image J (National Institutes of Health).
Statistical analysis. Genetic interaction was tested by two-way ANOVA
when a signiﬁcant difference was found by a t test between double mutants
and Nestin-Cre mice. In the absence of interaction, contribution of each gene
to the double knockout phenotype is displayed (two-way ANOVA). In the
presence of interaction, differences between single mutants and Nestin-Cre
mice were tested by one-way ANOVA and displayed. All results are expressed
as means  SE. Tests were performed using GraphPad Prism (Graphpad, San
Diego, CA).
RESULTS
Nestin-Cre mice have a metabolic phenotype. Surpris-
ingly, the Nestin-Cre mice in our study had consistently
smaller body weight and length than ﬂoxed mice on the
standard diet (online appendix Fig. S1A and S1B). In
addition, Nestin-Cre mice had higher adiposity and circu-
lating leptin levels than ﬂoxed mice (online appendix Fig.
S1C and S1D). Nestin-Cre mice were also less tolerant to
glucose challenge while slightly more sensitive to insulin
administration than ﬂoxed mice (online appendix Fig. S1E
and S1F and supplementary RESULTS).
On an HFD, Nestin-Cre mice gained less weight than
ﬂoxed mice over time (online appendix Fig. S2A). Body fat
content and circulating leptin levels were not signiﬁcantly
different between the two genotypes after 13 weeks on the
HFD (Fig. S2B and S2C). Nestin-Cre mice maintained a
greater sensitivity to insulin than ﬂoxed mice that became
insulin resistant and had lower basal circulating insulin
levels (Fig. S2D and S2E). However, both genotypes
became similarly glucose intolerant (Fig. S2F). In light of
such a considerable metabolic phenotype, we used Nestin-
Cre mice as the control line for our studies with Socs-3/
Ptpn1 mice in order to control for the effect of the
Nestin-Cre transgene.
Combined inactivation of Socs-3 and Ptpn1 reveals
synergistic effects on body size. Brain-speciﬁc com-
bined gene inactivation was conﬁrmed in double-mutant
mice using real-time quantitative PCR (online appendix
Fig. S3). Analysis of growth of mice deﬁcient for either
SOCS-3 or PTP-1B or both in brain revealed that double
mutants had signiﬁcantly lower weight than single mutants
and Nestin-Cre mice after 7 weeks on the standard diet
(Fig. 1A). Socs-3 mutants were lighter than Ptpn1 mutants
and Nestin-Cre mice across several weeks. However, body
weight curves of Ptpn1 mutants and Nestin-Cre mice were
similar. Interestingly, Socs-3 and Ptpn1 genes interact in a
synergistic manner: the effect observed with combined
deletions was larger than the sum of the effects of each
gene taken independently (Fig. 1A, note f). Thus, on a
Socs-3–null background, central inactivation of Ptpn1
affects body weight homeostasis.
The substantially lower weight of double-mutant mice
was associated with a shorter body length (Fig. 1B). As for
body weight, both gene deletions contributed synergisti-
cally to this phenotype. In line with their smaller size,
double mutants had the lowest circulating IGF-1 levels
(Fig. 1C). The low body weight of the double mutants
might be attributed entirely to their short length. However,
double mutants had signiﬁcantly lower BMI (Fig. 1D). This
suggests that their body composition is substantially
altered.
Double mutants have low adiposity on the standard
diet because of a lack of brain SOCS-3. Compared with
Nestin-Cre mice, fat mass at 19 weeks was similarly
reduced in Socs-3 and double mutants (Fig. 2A). Normal-
ization to body weight (Fig. 2B) or to body length using fat
mass index (fat mass/height squared) (Fig. 2C) led to the
same observation. A two-way analysis indicates that the
low adiposity of double knockout mice is attributed to
the absence of brain SOCS-3, whereas the absence of
PTP-1B does not contribute to this phenotype. In addition,
lean mass was signiﬁcantly reduced only in double mu-
tants (Fig. 2A). This was also true when normalized to
body length (not shown). In addition to reduced fat mass,
this is likely to contribute to their low BMI.
Various fat depots were dissected from 7- to 8-month-
old animals and weighed. Visceral fat pads (retroperito-
neal, perirenal, and gonadal), but not subcutaneous pads,
were signiﬁcantly reduced in double mutants compared
with Nestin-Cre mice (Fig. 2D). At that age, both gene
deletions contributed to this phenotype, although absence
of SOCS-3 had the main effect. In addition, whereas
visceral fat pads were signiﬁcantly larger than subcutane-
ous pad in Nestin-Cre and single-mutant mice (Fig. 2E),
both depots accounted for similar fractions of total dis-
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relative contribution of fat depots to body weight is
changed when both Socs-3 and Ptpn1 genes are deleted in
the brain.
In line with lower adiposity, leptin levels were reduced
in double mutants, and this was mainly attributed to the
absence of SOCS-3 (Fig. 3A). However, neither food intake
nor ambulatory activity was different from Nestin-Cre
mice (Fig. 3B and C). A trend toward higher energy
expenditure (oxygen consumption and generated heat per
kilogram body weight) was observed but did not reach
signiﬁcance (Fig. 3D and E). Respiratory quotient was
unchanged among mutants (Fig. 3F).
Double mutants gain less weight on an HFD than
Nestin-Cre mice. Both brain Socs-3– and Ptpn1-null mice
were reported to be protected against DIO (34,35). We
therefore examined response to DIO in our cohorts. Dou-
ble mutants weighed signiﬁcantly less than Nestin-Cre
mice until week 14 on the HFD (Fig. 4A). Despite the
weight effect of the Nestin-Cre transgene, we found that
double mutants gained signiﬁcantly less weight than Nes-
tin-Cre mice over the ﬁrst 10 weeks on the HFD (P  0.05;
comparing Nes and N-P1/S3-KO curves). Both gene dele-
tions contributed to this subtle reduction in weight gain
(two-way analysis at week 10: interaction: NS, P1: P 
0.01, S3: P  0.01). This protection was nonetheless not
total since double mutants still gained substantial weight
on the HFD over those on the standard diet (Fig. 4B).
Fat mass was measured after 13 weeks on the HFD (Fig.
4C). Double mutants had signiﬁcantly lower adiposity than
Nestin-Cre mice, and deletion of Ptpn1 accounted for this
phenotype (two-way ANOVA). However, after 5–7 months
on the HFD, no signiﬁcant difference in fat pad weights
was detected between genotypes (Fig. 4D). This may
reﬂect a ceiling effect. Nonetheless, visceral fat pads were
smaller than subcutaneous depots in double mutants,
whereas the opposite was observed for Nestin-Cre and
Ptpn1 mutants (Fig. 4E), in line with our observations on
the standard diet.
Double mutants have high energy expenditure on the
HFD. After 11–13 weeks on the HFD, double mutants had
low circulating leptin levels compared with Nestin-Cre
mice. This phenotype was attributed to both Ptpn1 and
Socs-3 deletions (Fig. 5A). Although food intake and
ambulatory activity were not changed (Fig. 5B and C),
oxygen consumption and heat generated were signiﬁcantly
increased in double-mutant mice (Fig. 5D and E). In both
cases, deletion of Socs-3 accounted for most of the vari-
ance (two-way ANOVA). Respiratory quotient was not
changed (Fig. 5F). All together, our data indicate that
double-mutant mice are more resistant to DIO than Nestin-
Cre mice and that this resistance may be attributed to
increased energy expenditure.
Leptin sensitivity is enhanced in mice lacking brain
SOCS-3 and PTP-1B. The ﬁnding of normal food intake
and normal to high energy expenditure of double-mutant
mice in the context of low circulating leptin levels suggest
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FIG. 1. Double-mutant mice have reduced body length and BMI. A: Body weight curve of double mutants (N-P1/S3-KO; n  8), Ptpn1 (N-P1-KO;
n  12), and Socs-3 (N-S3-KO; n  13) single mutants and Nestin-Cre control mice (Nes; n  6) on the standard diet. One-way ANOVA test
followed by Tukey post test gives the following for every time points unless speciﬁed: a, P < 0.01 vs. Nes; b, P < 0.01 vs. N-P1-KO; c, P < 0.05
vs. N-S3-KO after week 7; d, P < 0.05 vs. Nes (except weeks 6, 8, and 16); e, P < 0.05 vs. N-P1-KO between weeks 8 and 15. Interaction between
Socs-3 and Ptpn1 genes is considered signiﬁcant (P < 0.05) after week 7 by two-way ANOVA (f). B: Body length at 5 months (bottom) and picture
of representative mice for each genotype (top). Genetic interaction is statistically signiﬁcant by two-way ANOVA. C: Total plasma IGF-1 levels
(n  5–6). Interaction between both genes is not signiﬁcant. D: Double mutants have low BMI. Genetic interaction is signiﬁcant by two-way
ANOVA. Statistical analysis displayed on top of bars and plots was obtained by one-way ANOVA followed by Dunnett test versus Nes. NS, not
signiﬁcant. ***P < 0.001. Boxed text is result of two-way ANOVA, indicating whether genetic interaction (i) was found. If not, contribution of
Ptpn1 (P1) and Socs-3 (S3) to the double-mutant phenotype is displayed.
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we examined sensitivity to recombinant leptin.
Upon repeated daily injections of recombinant leptin,
27- to 31-week-old single and double knockout mice
demonstrated a greater body weight loss than Nestin-Cre
mice on the second day of treatment (Fig. 6A, day 5). After
3 days of injections, only double mutants presented a
signiﬁcant body weight loss compared with Nestin-Cre
mice. Two-way ANOVA tests indicate that combined gene
deletions had similar additive effects. However, in contrast
to body weight, we were unable to detect a signiﬁcant
difference between mutant and Nestin-Cre mice in leptin-
induced anorexia (Fig. 6B).
STAT3 plays a role in propagating the leptin signal and
is phosphorylated upon leptin binding to its receptor.
Under basal conditions, there were more cells in hypotha-
lamic arcuate nucleus (ARN) with high levels of pSTAT3 in
double mutants (Fig. 6C), an effect accounted for by Ptpn1
deletion (two-way ANOVA). Upon leptin injections, only
Socs-3 and double mutants presented a signiﬁcant in-
crease in the number of ARN cells with high levels of
pSTAT3.
The ventromedial nucleus of the hypothalamus (VMN) is
another important leptin-responsive brain region involved
in body weight and glucose homeostasis (4,39). As in the
ARN upon leptin action, the number of leptin responsive
pSTAT3 cells in the VMN was higher in Socs-3 and
double mutants, and absence of Socs-3 accounted for the
phenotype displayed by double mutants.
Despite differences in STAT3 activation, no signiﬁcant
differences were detected in transcript levels of anorexi-
genic Pomc1 and orexigenic Agrp and Npy genes in the
ARN between the genotypes, either basally or upon leptin
administration in 7- to 11-month-old mice (not shown).
This is in accordance with the absence of signiﬁcant
differences in daily food intake in our cohorts.
Glucose homeostasis is improved by combined brain
deletions of SOCS-3 and PTP-1B. Because increased
adiposity and leptin resistance are associated with insulin
resistance leading to diabetes, we evaluated glucose ho-
meostasis in our double mutants, both on the standard diet
and HFD.
Glycemia was not different between genotypes on chow
diet (Fig. 7A). However, double mutants had signiﬁcantly
lower blood glucose levels after 11–13 weeks on the HFD
than Nestin-Cre mice. Socs-3 and Ptpn1 deletions had
similar additive effects on lowering glucose levels (Fig.
7B). In addition, circulating insulin levels were lower in
double mutants on standard diet and a trend toward low
insulin levels on the HFD was observed (Fig. 7C and D).
Interestingly, brain speciﬁc Socs-3 deletion accounted
for the low insulinemia displayed by double mutants (Fig.
7C, two-way ANOVA). All together, these observations
suggest that double mutants are more insulin sensitive
than controls on both diets.
Glucose tolerance tests revealed that on both diets, area
under the curve was signiﬁcantly smaller for double
mutants compared with Nestin-Cre mice (Fig. 7E and F).
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FIG. 2. Double mutants have as low adiposity on the standard diet as Socs-3 mutants. A and B: Fat and lean mass was measured by EchoMRI at
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quite reach signiﬁcance and Socs-3 deletion had the main
effect. On HFD, overnight-fasted glucose levels were lower
for Ptpn1 (P  0.01) and double mutants (P  0.001)
before injections (Fig. 7F). Both gene deletions had addi-
tive effects on improving glucose tolerance, although
Socs-3 contributed the most.
Sensitivity to insulin injections was improved for double
mutants on both diets as well. On the standard diet, both
genes contributed equally to this effect (Fig. 7G). On the
HFD, double-mutant mice had signiﬁcantly lower basal
glucose levels than Nestin-Cre mice (P  0.001). Deletion
of Socs-3 gene did not quite signiﬁcantly affect insulin
tolerance, while Ptpn1 deletion had a main effect (two-
way ANOVA) (Fig. 7H). Hence, insulin sensitivity of dou-
ble mutants on HFD is improved to an extent comparable
to brain Ptpn1 mutants, while on the standard diet it
reﬂects the similar additive protective effects of each
deletion.
DISCUSSION
Although obesity is typically associated with high circulat-
ing leptin levels, most obese animals and humans maintain
elevated energy intake. Furthermore, in obese rodents,
resistance to exogenous leptin led to the concept of leptin
resistance (13). Thus, approaches that increase leptin
sensitivity may provide insights into developing novel
therapies for obesity and associated diseases. SOCS-3 and
PTP-1B act as endogenous inhibitors of cytokine signaling
pathways. Importantly, both factors suppress leptin as
well as insulin signaling, which makes them potential
targets for type 2 diabetes treatment. Indeed, PTP-1B
inhibitors are under development or testing in antidiabetic
clinical trials (40,41).
To evaluate the possibility that Socs-3 and Ptpn1 genes
might interact in the regulation of body weight and glucose
homeostasis, mice with combined gene deletions in the
brain were generated. In the course of these experiments,
the Nestin-cre mice, used to mediate gene inactivation,
appeared to have an intrinsic metabolic phenotype includ-
ing reduced body weight and length in the context of
increased adiposity on the standard diet but less weight
gain on the HFD than ﬂoxed controls. These intrinsic
phenotypes may mask some of the phenotypes previously
reported by brain-speciﬁc single-gene mutants. For exam-
ple, both brain single mutants were reported to be resis-
tant to DIO compared with ﬂoxed siblings (34,35).
However, in our hands, single mutants were not better
protected against DIO than Nestin-Cre mice (one-way
analysis), whereas single mutants were when compared
with ﬂoxed siblings (not shown). Hence, phenotypes
caused by presence of the Nestin-Cre transgene are likely
to mask subtle phenotypes caused by absence of either
SOCS-3 or PTP-1B in our Nestin-Cre–mediated knockout
mice.
Phenotypic discrepancies were observed for single mu-
tants between the pioneer studies with the brain Ptpn1 or
Socs-3 knockout (34,35) and ours. Those discrepancies
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mice (see above), from diet compositions (different in all
three studies), and from genetic background differences.
Indeed, marked differences in feeding, energy expenditure,
and response to DIO have been reported between C57BL/6
and 129 genetic backgrounds (42).
The ﬁnding of a phenotype of Nestin-Cre mice suggests
that these mice must be used with caution in metabolic
studies. Although our data does not address whether the
above described phenotypes are attributed to disruption of
gene sequences at the locus of the transgene insertion or
to potential Cre toxicity in particular cell types, it has
previously been shown that high Cre activity levels are
toxic to neural stem/progenitor cells (43).
Despite the metabolic phenotype of Nestin-Cre mice,
combined inactivation in brain of Ptpn1 and Socs-3 re-
vealed synergistic interactions and additive effects, which
ranged from the addition of similar effects to primary and
gene-speciﬁc effects. No antagonistic functions, some of
which may lead to negation of an effect, were revealed.
Importantly, the current study was the ﬁrst direct compar-
ison of the roles of SOCS-3 and PTP-1B in siblings or
closely related single knockout mice. The contribution of
each gene to the phenotypes observed in double mutants
is summarized in Table 1.
Body length and body weight were the only parame-
ters that revealed synergism between SOCS-3 and
PTP-1B actions. Combined brain deletions led to a short
body length phenotype. We examined aspects of the
growth hormone axis: double mutants had the lowest
IGF-1 levels and trended to the lowest growth hormone
levels (not shown). This suggests that the growth hor-
mone/IGF-1 axis is centrally affected by loss of SOCS-3
and PTP-1B. Both SOCS-3 and PTP-1B bind to and sup-
press signaling through the growth hormone and IGF-1
receptors (44–47). Both growth hormone and IGF-1 exert a
feedback onto hypothalamic neurons that leads to suppres-
sion of growth hormone pituitary secretion. Double mu-
tants might have increased hypothalamic sensitivity to
circulating growth hormone and IGF-1, leading to a reduc-
tion in growth hormone which in turn leads to reduced
IGF-1 secretion and small body size.
This synergism suggests that when only one factor is
deleted, compensatory mechanisms substitute to maintain
linear growth, and these mechanisms cannot be sustained
when both proteins are absent. As we did not observe any
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Boxed text, two-way ANOVA.
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Ptpn1 mutants, respectively, compared with Nestin-Cre
mice (Fig. S3), possible compensatory mechanisms do not
involve upregulation of expression of the other inhibitor in
single mutants.
In addition, both SOCS-3 and PTP-1B suppress signaling
through receptor-associated Janus kinase 2 (JAK2) and
tyrosine kinase receptors, although they have different
modes of action: SOCS-3 can interact with and block JAK2
activity, promote degradation of insulin receptor substrate
proteins and receptor complex via its SOCS box, and
block access to speciﬁc cytokine receptor tyrosine resi-
dues, whereas PTP-1B is an endoplasmic reticulum–asso-
ciated enzyme that dephosphorylates and inactivates these
same partners, probably following endocytosis of the
ligand receptor complex (21–24). We might speculate that
in absence of SOCS-3, fewer cytokine receptor complexes
may be targeted for degradation by the proteasome,
thereby increasing the pool of recycled receptors and
leading to increased signal transduction. In the absence of
PTP-1B, internalized receptor complexes might remain
phosphorylated and hence active for a longer period of
time. Combined absence of SOCS-3 and PTP-1B might
then result in multiplicative effects of absence of each
factor on stability and activity of the same target molecule.
However, one might then wonder why this synergistic
effect is only detected for body length and not for adiposity
or other parameters. Further investigation is needed to
understand the molecular basis of this synergy.
Most phenotypes displayed by the double knockout
mice resulted from the addition of the phenotypes dis-
played by the single knockout mice. For example, inacti-
vation of both genes contributed to the partial protection
against DIO and associated hyperglycemia and glucose
intolerance displayed by double mutants. Protection
against DIO was associated with higher energy expendi-
ture, suggesting that the sympathetic tone may be stimu-
lated in absence of both factors.
Additive effects may underlie independent functions,
indicating that the biological roles of SOCS-3 and PTP-1B
do not fully overlap. These factors may act on different
downstream pathways that contribute to the same pheno-
types or on the same pathways but on different targets.
However, we cannot rule out that some dominant epistatic
effects might not have been revealed because of the
difﬁculty in obtaining large cohorts of single- and double-
conditional knockout mice. Interestingly, some pheno-
types displayed by the double mutants are largely
attributed to the absence in the brain of either SOCS-3 or
PTP-1B. For instance, Ptpn1 deletion transiently has a
main effect on adiposity levels on HFD.
In contrast, deletion solely of Socs-3 is responsible for
low adiposity and low insulin levels on the standard diet.
Although mice with single deletions had same levels of
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tants were leaner than Ptpn1 mutants with lower circulat-
ing leptin levels. This suggests that leptin sensitivity is
enhanced in Socs-3 mutants. However, both single mu-
tants lost similar amount of weight upon repeated leptin
administration, indicating comparable leptin sensitivity.
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input or an increase in energy output, might account for
such discrepancies.
First, the low power of our CLAMS study may prevent a
thorough assessment of energy expenditure. Alternatively,
the underlying difference may be beyond the limit of
detection of currently available equipment. In fact, upon
HFD feeding that challenges metabolic regulatory mecha-
nisms, Socs-3 deletion accounts for most of the double
knockout increase in energy expenditure, suggesting en-
hanced energy expenditure in Socs-3 mutants. In addition,
a difference in body weight between single mutants is
already detectable at 8 weeks on the standard diet and
increases at a slow rate afterward. As energy expenditure
was assessed at 6–7 months, the older age may prevent the
detection of a small change in energy expenditure. In-
creased energy expenditure may result from increased
sympathetic activity. Low insulin levels of Socs-3 mutants
might then be a consequence of high sympathetic activity,
which was shown to affect the bioactivity of a bone-
derived insulin segretagogue (48). In turn, low insulin
levels might contribute to reduced adipose mass.
Second, our study does not address possible differences
in intestinal absorption. Possibly, absence of SOCS-3 af-
fects sympathetic and/or vagal innervations of the diges-
tive tract. Further investigation is required to test these
two hypotheses.
Socs-3 mutants had a larger number of pSTAT3 hypo-
thalamic cells than Pptn1 mice revealed by immunohisto-
chemistry upon leptin administration, despite having
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FIG. 7. Glucose homeostasis is enhanced by combined brain deletions of Socs-3 and Ptpn1 genes. A: Ad libitum blood glucose on the standard diet
(n  6–12). B: Six-hour fast blood glucose levels after 11–13 weeks on the HFD (n  7–12). C: Ad libitum plasma insulin levels on the standard
diet (n  5–11). D: Six-hour fast plasma insulin levels after 11–13 weeks on the HFD (n  6–8). E: Glucose tolerance test after 20–22 weeks on
the standard diet (n  5–13). F: Glucose tolerance test after 19 weeks on the HFD (n  7–12). G: Insulin sensitivity test after 21–23 weeks on
the standard diet (n  6–11). H: Insulin sensitivity test after 20 weeks on the HFD (n  7–12). NS, not signiﬁcant. *P < 0.05 by t test. Same test
was performed, with AUC and P value for double mutants are displayed (E–H). Interaction between the genes is considered not signiﬁcant for
all panels. Boxed text, two-way ANOVA.
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weight loss. This contradiction is only apparent because
the immunochemical assay only reveals a subset of leptin
sensitive cells (those with large amounts of pSTAT3),
whereas not all cells may respond equally well to leptin.
The number of poorly versus highly leptin responsive cells
might differ between genotypes. Moreover, absence of
PTP-1B resulted in an increased number of ARN pSTAT3
cells under basal conditions, suggesting enhanced basal
leptin sensitivity in Ptpn1 and double mutant arcuate
nuclei.
Surprisingly, fat depots are not equally affected by
combined loss of SOCS-3 and PTP-1B in brain. Indeed,
double mutants presented a reduction in visceral fat pads,
whereas subcutaneous pads were less affected. Subcuta-
neous fat is believed to have beneﬁcial effects on glucose
tolerance and insulin sensitivity as opposed to visceral fat
(49). Therefore, this phenotype in turn may contribute to
the enhanced insulin and glucose sensitivity observed in
double mutants.
In our study, inactivation of SOCS-3 and PTP-1B was
achieved in the whole brain and was not cell-type speciﬁc.
Peptidic hormone and cytokine effects are not conﬁned to
the hypothalamus and leptin, for example, modulates the
mesolimbic dopamine system (5,7,9) and long-term de-
pression in the hippocampus (50). Hence, other behaviors
than those reported here may be altered in the double
mutants. In addition, the JAK/STAT pathway is involved in
cell proliferation and SOCS-3 and PTP-1B suppress this
pathway. Although we did not observe any gross histolog-
ical abnormalities in brain of mutant mice, we cannot rule
out that inactivation of Socs-3 and Ptpn1 may in turn affect
neural development as well as neurogenesis in adulthood
(51).
We here provided evidence that abolishing both SOCS-3
and PTP-1B cytokine suppressor activities in brain is
beneﬁcial for body weight and glucose homeostasis be-
cause of their additive effects for most of the investigated
phenotypes. We also found evidence for protein-speciﬁc
roles and for synergism in the case of body length.
Importantly, our study suggests that using a combination
of inhibitors for SOCS-3 and PTP-1B may improve thera-
peutic trials targeting obesity and type 2 diabetes.
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